News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP ...
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat ...
YouTube on MSN
Peptides: What you need to know (Dr Nick Norwitz MD PhD)
“What Are Your Thoughts on Peptides?” I can’t tell you how many times I’ve been asked that question lately. Over and over ...
Morning Overview on MSN
Intismeran autogene plus Keytruda dropped melanoma recurrence by close to 50% over five years in a Moderna-Merck-NYU trial unveiled at ASCO
Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside Keytruda saw their risk of disease ...
Stonehenge has always invited big questions, but one of its most stubborn mysteries sits low to the ground. The Altar Stone, ...
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...
Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with Vanrafia vs placebo, based on ...
Analyses demonstrate consistent positive signals across endpoints in AKI patientsFindings derived from post hoc analysis of 101 patients also experiencing respiratory distressNew data and analysis to ...
A clinical trial is underway at La Trobe University and its Athens counterpart for an Australian-made probiotic, ...
Bempedoic acid may prevent dangerous blood clots from forming in addition to reducing risk for major cardiovascular events vs ...
Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans June 1, 2026 8:00 ...
Objectives To determine the prevalence, patterns and correlates of medicinal herb use in a rural Iranian population and to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results